Melissa Garnett
Psychiatric/Mental Health · Hilo, HINPI 1114384229
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,554, more than ten times the $222 reported in 2022. Among psychiatric/mental health clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$926
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$863
- Teva Pharmaceuticals USA, Inc.$821
- Indivior Inc.$611
- Johnson & Johnson$601
- plus $1K from 4 others
What the payments were for
- Food & beverage$6,191100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 51 | $1,265 |
| Otsuka America Pharmaceutical, Inc. | 28 | $926 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $863 |
| Teva Pharmaceuticals USA, Inc. | 27 | $821 |
| Indivior Inc. | 21 | $611 |
| Johnson & Johnson | 36 | $601 |
| Lundbeck LLC | 17 | $496 |
| E.r. Squibb & Sons, L.L.C. | 11 | $398 |
| Neurocrine Biosciences, Inc. | 4 | $166 |
| AbbVie | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$260
- ABILIFY ASIMTUFII$145
- COBENFY$144
- INGREZZA$125
- Austedo XR$121
- REXULTI$120
How this compares
$6,191 in reported general payments places this provider in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 120 | $393,348 |
| RexultiBrexpiprazole | 128 | $217,536 |
| AristadaAripiprazole Lauroxil | 74 | $178,367 |
| VraylarCariprazine Hcl | 71 | $111,205 |
| Abilify MaintenaAripiprazole | 41 | $108,247 |
| PerserisRisperidone | 22 | $63,018 |
| LybalviOlanzapine/Samidorphan Malate | 36 | $62,748 |
| CaplytaLumateperone Tosylate | 18 | $30,256 |
| Paliperidone ErPaliperidone | 102 | $24,744 |
| Lurasidone Hcl | 36 | $12,383 |
| Aripiprazole | 126 | $12,333 |
| Divalproex Sodium ErDivalproex Sodium | 137 | $11,559 |
| Quetiapine Fumarate | 206 | $9,423 |
| Gabapentin | 316 | $8,200 |
| Clozapine | 53 | $7,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $601 | $393,348120 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $926 | $325,782169 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,265 | $241,115110 claims |
| AbbVieVraylar | $45 | $111,20571 claims |
| Indivior Inc.Perseris | $611 | $63,01822 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $863 | $30,25618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.
Other psychiatric/mental health in Hilo
- Tammy WheelerHilo$5K
- Allen NovakHilo$3K
- Ryan GarnettHilo$2K
- Julie AgnoHilo$907
- Tracy ThornettHilo$806
- Beth Ananda-StoutHilo$408
- J D BrandmanHonolulu$63K
- Jeremy CreekmoreAiea$13K
- Kuuleikuponookealoha NaahieluaAiea$8K
- Jacqueline WernerKapolei$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.